Bausch Health Companies IncTSX:BHCView on NYSE
- LAST PRICE11.1700
- TODAY'S CHANGE (%)-0.2800 (-2.4454%)
- Bid / Lots11.1400/ 5
- Ask / Lots11.1900/ 1
- Open / Previous Close11.3900 / 11.4500
- Day Range
- 52 Week Range
- Volume193,293
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BHC |
|---|---|---|
| 09:32 ET | 700 | 11.39 |
| 09:37 ET | 200 | 11.38 |
| 09:39 ET | 500 | 11.38 |
| 09:42 ET | 100 | 11.37 |
| 09:44 ET | 500 | 11.43 |
| 09:46 ET | 100 | 11.42 |
| 09:50 ET | 600 | 11.4 |
| 09:51 ET | 400 | 11.42 |
| 09:53 ET | 200 | 11.44 |
| 09:55 ET | 100 | 11.43 |
| 09:57 ET | 600 | 11.43 |
| 10:00 ET | 300 | 11.43 |
| 10:04 ET | 400 | 11.42 |
| 10:06 ET | 300 | 11.44 |
| 10:08 ET | 1000 | 11.44 |
| 10:09 ET | 300 | 11.43 |
| 10:11 ET | 900 | 11.41 |
| 10:13 ET | 1600 | 11.4 |
| 10:15 ET | 400 | 11.39 |
| 10:18 ET | 200 | 11.38 |
| 10:20 ET | 200 | 11.35 |
| 10:22 ET | 100 | 11.38 |
| 10:24 ET | 900 | 11.36 |
| 10:26 ET | 300 | 11.38 |
| 10:27 ET | 300 | 11.37 |
| 10:29 ET | 1500 | 11.37 |
| 10:36 ET | 600 | 11.42 |
| 10:38 ET | 400 | 11.41 |
| 10:40 ET | 100 | 11.41 |
| 10:42 ET | 400 | 11.41 |
| 10:45 ET | 500 | 11.42 |
| 10:54 ET | 700 | 11.43 |
| 10:58 ET | 300 | 11.43 |
| 11:00 ET | 300 | 11.44 |
| 11:03 ET | 200 | 11.43 |
| 11:05 ET | 200 | 11.44 |
| 11:12 ET | 600 | 11.44 |
| 11:16 ET | 100 | 11.435 |
| 11:20 ET | 500 | 11.435 |
| 11:21 ET | 400 | 11.44 |
| 11:23 ET | 800 | 11.45 |
| 11:25 ET | 400 | 11.45 |
| 11:27 ET | 2700 | 11.43 |
| 11:36 ET | 100 | 11.41 |
| 11:38 ET | 100 | 11.4 |
| 11:39 ET | 100 | 11.39 |
| 11:41 ET | 1000 | 11.38 |
| 11:45 ET | 1200 | 11.39 |
| 11:48 ET | 500 | 11.39 |
| 11:52 ET | 1100 | 11.37 |
| 11:57 ET | 1500 | 11.36 |
| 11:59 ET | 200 | 11.38 |
| 12:03 ET | 100 | 11.37 |
| 12:06 ET | 1400 | 11.37 |
| 12:14 ET | 100 | 11.37 |
| 12:24 ET | 2100 | 11.36 |
| 12:32 ET | 100 | 11.36 |
| 12:33 ET | 100 | 11.35 |
| 12:35 ET | 100 | 11.34 |
| 12:37 ET | 500 | 11.34 |
| 12:42 ET | 400 | 11.34 |
| 12:46 ET | 100 | 11.35 |
| 12:48 ET | 100 | 11.35 |
| 12:51 ET | 500 | 11.34 |
| 12:55 ET | 2600 | 11.31 |
| 12:57 ET | 1600 | 11.32 |
| 01:02 ET | 200 | 11.31 |
| 01:04 ET | 100 | 11.32 |
| 01:13 ET | 400 | 11.33 |
| 01:15 ET | 600 | 11.32 |
| 01:18 ET | 200 | 11.31 |
| 01:22 ET | 300 | 11.31 |
| 01:27 ET | 200 | 11.32 |
| 01:33 ET | 300 | 11.33 |
| 01:36 ET | 100 | 11.33 |
| 01:38 ET | 400 | 11.33 |
| 01:42 ET | 300 | 11.33 |
| 01:51 ET | 500 | 11.34 |
| 01:54 ET | 1300 | 11.33 |
| 01:56 ET | 1700 | 11.32 |
| 01:58 ET | 100 | 11.32 |
| 02:00 ET | 19200 | 11.32 |
| 02:05 ET | 1100 | 11.315 |
| 02:07 ET | 400 | 11.32 |
| 02:14 ET | 400 | 11.34 |
| 02:16 ET | 300 | 11.34 |
| 02:18 ET | 1500 | 11.35 |
| 02:21 ET | 100 | 11.355 |
| 02:23 ET | 300 | 11.36 |
| 02:25 ET | 100 | 11.365 |
| 02:30 ET | 100 | 11.37 |
| 02:32 ET | 1600 | 11.36 |
| 02:41 ET | 3200 | 11.35 |
| 02:43 ET | 300 | 11.35 |
| 02:45 ET | 100 | 11.345 |
| 02:48 ET | 7100 | 11.32 |
| 02:52 ET | 6600 | 11.32 |
| 02:56 ET | 100 | 11.325 |
| 03:03 ET | 200 | 11.32 |
| 03:06 ET | 2300 | 11.32 |
| 03:08 ET | 500 | 11.32 |
| 03:10 ET | 400 | 11.32 |
| 03:15 ET | 100 | 11.325 |
| 03:17 ET | 100 | 11.33 |
| 03:19 ET | 500 | 11.33 |
| 03:26 ET | 2300 | 11.335 |
| 03:30 ET | 1200 | 11.32 |
| 03:32 ET | 1400 | 11.32 |
| 03:33 ET | 200 | 11.31 |
| 03:35 ET | 7800 | 11.26 |
| 03:39 ET | 24500 | 11.22 |
| 03:42 ET | 600 | 11.23 |
| 03:44 ET | 1100 | 11.23 |
| 03:46 ET | 3000 | 11.25 |
| 03:48 ET | 600 | 11.25 |
| 03:50 ET | 5900 | 11.2 |
| 03:51 ET | 8500 | 11.18 |
| 03:55 ET | 3000 | 11.18 |
| 03:57 ET | 11800 | 11.16 |
| 04:00 ET | 29100 | 11.17 |
Nov 18, 2024
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis, from 8:13AM ET on Monday Nov 18, 2024 by Dow Jones
8:13AM ET on Monday Nov 18, 2024 by Dow JonesPrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS, from 8:02AM ET on Monday Nov 18, 2024 by Dow Jones
8:02AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 1, 2024
DJ Bausch Health Is Maintained at Sector Perform by RBC Capital, from 11:36AM ET on Friday Nov 01, 2024 by Dow Jones
11:36AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 31, 2024
DJ Bausch Health Shares Rise on FY Outlook Upgrade, 3Q Beat, from 10:29AM ET on Thursday Oct 31, 2024 by Dow Jones
10:29AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
*DJ Bausch Health 3Q Rev $2.51B >BHC, from 4:18PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:18PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bausch Health Companies Inc | 4.2B | -16.5x | --- |
Green Thumb Industries Inc | 2.8B | 34.3x | --- |
Cresco Labs Inc | 6.2B | -5.5x | --- |
Glass House Brands Inc | 491.3M | -10.0x | --- |
Cannabist Company Holdings Inc | 69.7M | -0.4x | --- |
Ayr Wellness Inc | 110.4M | -0.3x | --- |
Company Information
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products, and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Contact Information
- Headquarters
- 2150 St. Elzear Blvd. WestLAVAL, QC, Canada H7L 4A8
- Phone
- 514-744-6792
- Fax
- 514-744-6792
Executives
- Independent Chairman of the Board
- John Paulson
- Chief Executive Officer, Director
- Thomas Appio
- Chief Financial Officer, Executive Vice President
- Jean-Jacques Charhon
- Executive Vice President, General Counsel
- Seana-Lyn Carson
- Senior Vice President, Chief Accounting Officer, Controller
- John Barresi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2B |
|---|---|
Revenue (TTM) | $13.2B |
Shares Outstanding | 367.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-0.68 |
Book Value | $-3.91 |
P/E Ratio | -16.5x |
Price/Sales (TTM) | 0.3 |
Price/Cash Flow (TTM) | 2.8x |
Operating Margin | 14.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
